Clinical Research Directory

Inclusion criteria * Adequate organ and bone marrow function. * In Part A (dose escalation), participants must be aged ≥ 18 years at the time of signing the informed consent. In Part B (dose optimization/expansion), participants must be at least 15 years of age. * Histologically confirmed documented diagnosis of r/r cHL based on criteria established by the World Health Organization * Must provide FFPE baseline tumour tissue to meet the minimum tissue requirement for central MTAP expression determination. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Module 1 (cHL): * At least 1 radiographically measurable, and/or FDG-avid lymphoma lesion \> 1.5 cm. * Participants must have documented r/r active disease, must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL, and must have exhausted all available therapies with demonstrated clinical benefit. Exclusion criteria * Any significant laboratory finding or any severe and uncontrolled medical condition. * Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression. * Serologic active HBV or HCV infection. * Known to have tested positive for HIV. * Active gastrointestinal disease or other condition that will interfere with oral therapy. * Any of the following cardiac criteria: * Mean resting QTcF \> 470 msec or clinically important abnormalities in rhythm (ventricular arrhythmias and uncontrolled atrial fibrillation) * Factors that increase the risk of QTc prolongation or risk of arrhythmic events * Cardiac procedures or conditions within the last 6 months: Coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or heart valve intervention vascular stent implantation, acute coronary syndrome / myocardial infarction, uncontrolled angina pectoris, use of therapeutic anti-coagulation for treatment of active thromboembolic events. * Severe valvular heart disease * Congestive heart failure Grade II to Grade IV * Prior or current cardiomyopathy * Uncontrolled hypertension * Brain perfusion problems such as haemorrhagic or thrombotic stroke (including transient ischemic attacks) * Unresolved non-haematological toxicities of Grade \> 1 from prior anticancer therapy (excluding peripheral neuropathy, vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated. * History of another primary malignancy. * History of significant haemoptysis or haemorrhage within 4 weeks of the first dose of study treatment. * Requires ongoing immunosuppressive therapy, including systemic corticosteroids. * Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.